Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanoliposomal irinotecan with fluorouracil vs S-1 as second-line chemotherapy for unresectable advanced pancreatic cancer
jRCT1041210132Completed
- Start
- Jan 2022
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised trial in pancreatic cancer (PC) comparing S-1 monotherapy with Nanoliposomal irinotecan + fluorouracil (2 arms). Primary endpoint: Progression-free survival. Started Jan 2022; status: completed.
02
Drugs
nanoliposomal irinotecanfluorouraciltegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT1041210132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041210132.